Researchers argue that, in some situations where machine-learning models are used to allocate scarce resources or opportunities, randomizing decisions in a structured way may lead to fairer outcomes.
The heterogeneity of breast cancer makes identifying effective therapies challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results